Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Marathon's High-Priced Window May Not Stay Open Long

Executive Summary

Ongoing trial is intended to compare the newly approved steroid Emflaza with prednisone in DMD for efficacy and safety.


Related Content

Patient-Centered Promotion? Marathon's Non-Launch Of Emflaza Illustrates Challenge Of New Era
Gilead Buys Its Third Priority Review Voucher, But Is The Mania Over?
Marathon Gets Long-Known Duchenne Treatment On-Label, But Will Payers Respond?
Drug Pricing Bill May Make Six-Month ANDA Review Slower Than Eight-Month Review
Pharma’s Pricing Debate Splinters As US Political Confrontation Looms
Sarepta Snaps Up Gene Therapy Approaches to DMD
Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy
Priority Review Vouchers Appear To Be Dropping In Price
Handling Drug Price Spikes: A Sad Place To Be


Related Companies